Sagimet Biosciences spent the spring converting itself from a liver-disease story into a dermatology company, and the conversion is now funded. Management parked further work in metabolic liver disease unless a partner pays for it, then sold a large block of Series A stock to finance a United States registrational study of denifanstat in moderate-to-severe acne. The China partner already produced a clean late-stage win and an accepted local application, so the equity is no longer an early mechanism bet. It is a translation bet: can a once-daily fatty acid synthase inhibitor that worked in Chinese adults work in a larger, younger American trial.
The April financing reset the balance sheet. Gross proceeds of $175 million more than doubled the securities stack. Cash and marketable securities finished midyear near $258 million. That is the bull case in one line. The tension is that the United States protocol is not a photocopy of China. Co-primary endpoints use absolute lesion counts rather than percentage change, randomization is two-to-one rather than even, and more than half the planned patients are adolescents. A China win that does not repeat on those terms leaves a well-funded company with a parked liver program and a follow-on molecule still in first-in-human testing.
Second-quarter spending already shows the pivot. Research cost rose as acne work replaced a quieter first half, while overhead stayed roughly flat. First-in-human work on the follow-on inhibitor continues, and a topical formulation sits on the drawing board. The question the next year resolves is not whether fatty acid synthase is a real acne target. It is whether AURORA enrolls on time, whether the adolescent safety file stays clean, and whether the market is paying for a de-risked late-stage program or for a China result that does not travel.